Alpha Tau's Alpha DaRT Achieves 100% Local Disease Control in Pancreatic Cancer Trials at DDW 2026

Key Takeaways

• Alpha DaRT achieved 100% local disease control rate in evaluable pancreatic adenocarcinoma patients across two first-in-human trials
• Only 27% of patients experienced device-related adverse events, with nearly all resolving, demonstrating favorable safety profile
• Results presented at DDW 2026 represent significant progress for pancreatic cancer, one of the most challenging cancers to treat

---

Alpha Tau Medical announced breakthrough results from its Alpha DaRT pancreatic cancer trials at Digestive Disease Week (DDW) 2026, reporting a 100% local disease control rate in evaluable patients with a favorable safety profile.

The pooled analysis of two first-in-human trials evaluated Alpha DaRT, a targeted radiotherapy device, in 26 patients with pancreatic adenocarcinoma. The treatment demonstrated exceptional efficacy with complete local disease control in all evaluable patients, marking a significant milestone for pancreatic cancer treatment.

Safety Profile Shows Promise

The safety data revealed only 8 device-associated adverse events occurring in 7 of the 26 subjects (27%), with nearly all events resolving. This favorable safety profile is particularly noteworthy given pancreatic cancer’s reputation as one of the most aggressive and difficult-to-treat malignancies.

Revolutionary Approach to Pancreatic Cancer

Alpha DaRT represents a novel approach to treating solid tumors through targeted radiotherapy delivered directly to the tumor site. Unlike conventional treatments, this device-based therapy aims to provide localized treatment while minimizing systemic toxicity.

Pancreatic cancer remains one of the deadliest cancers, with a five-year survival rate below 10%. Current treatment options are limited and often associated with significant side effects, making Alpha DaRT’s results particularly significant for the oncology community.

Market Impact and Future Implications

The results position Alpha Tau favorably in the competitive pancreatic cancer treatment landscape, where companies like NovoCure, ViewRay, and Accuray are developing alternative approaches. The 100% local disease control rate, if confirmed in larger trials, could represent a paradigm shift in pancreatic cancer management.

While these Phase 1 results are encouraging, the small patient population and early trial stage require validation in larger, randomized controlled studies. The company will likely need to demonstrate durability of response and overall survival benefits to secure regulatory approval and market adoption.

Next Steps and Regulatory Pathway

Alpha Tau is expected to advance Alpha DaRT through standard regulatory pathways, with larger Phase 2 trials likely on the horizon. The company may also explore combination therapies and expansion into other solid tumor types based on these promising initial results.

The pancreatic cancer treatment market represents a significant opportunity, with limited effective options currently available. Success in this indication could open doors to partnerships with major oncology companies and accelerate the device’s development across multiple cancer types.

Investment and Development Outlook

The exceptional efficacy results, combined with the manageable safety profile, suggest strong potential for Alpha DaRT in addressing the substantial unmet need in pancreatic cancer treatment. However, investors and clinicians will closely monitor upcoming trial data to confirm these early promising signals in larger patient populations.

---

Frequently Asked Questions

What does the 100% local disease control rate mean for pancreatic cancer patients?

The 100% local disease control rate means that Alpha DaRT successfully prevented tumor growth or progression at the treatment site in all evaluable patients. This is particularly significant for pancreatic cancer, which is notoriously difficult to treat and has limited effective treatment options.

When will Alpha DaRT be available for pancreatic cancer patients?

Alpha DaRT is currently in Phase 1 trials and not yet commercially available. The company will need to complete larger Phase 2 and Phase 3 trials, then obtain regulatory approval from the FDA, which typically takes several years. Patients may access the treatment through clinical trials in the meantime.

How does Alpha DaRT compare to existing pancreatic cancer treatments?

Alpha DaRT offers a targeted radiotherapy approach delivered directly to the tumor, potentially reducing systemic toxicity compared to conventional chemotherapy. The 100% local disease control rate and 27% adverse event rate compare favorably to existing treatments, though larger trials are needed to confirm these benefits and establish overall survival advantages.